|
Subgroup analyses
|
N (%)
|
T2DM with DPN*
|
T2DM without DPN
|
SMD (95% CI) *
|
Heterogeneity
|
|---|
|
Mean + SD
|
Mean + SD
|
P-value**
|
I-squared
|
|---|
|
Ethnicity
|
America
|
3 (8.3)
|
2.54 + 1.02
|
2.61 + 0.85
|
0.07 (−0.24–0.37)
|
<0.001
|
84.92
|
|
Asia
|
29 (80.6)
|
2.75 + 0.96
|
2.82 + 0.88
|
0.07 (0.01–0.12)
|
<0.001
|
78.97
|
|
Europe
|
4 (11.2)
|
3.21 + 0.90
|
3.37 + 0.95
|
0.16 (− 0.06–0.38)
|
0.03
|
66.96
|
|
Study type
|
Case control
|
11 (30.6)
|
2.87 + 1.11
|
2.90 + 1.02
|
0.03 (− 0.05–0.11)
|
0.12
|
34.80
|
|
Cohort
|
3 (8.3)
|
2.82 + 0.60
|
2.98 + 0.62
|
0.16 (− 0.05–0.37)
|
<0.001
|
84.15
|
|
Cross-sectional
|
22 (61.1)
|
2.71 + 0.89
|
2.78 + 0.83
|
0.07 (0.01–0.13)
|
<0.001
|
80.52
|
|
Total (Random Effect Model)
|
36 (100)
|
2.78 + 0.98
|
2.86 + 0.91
|
0.08 (0.03–0.13)
|
<0.001
|
88.10
|
- *The negative combined effect suggests that the LDL mean was higher in the non- type 2 diabetic peripheral neuropathy comparable group i.e. diabetes whereas the positive value would suggest greater LDL mean values in the type 2 diabetic peripheral neuropathy group
- **P-values is calculated LDL mean between the T2DM with and without DPN
- All LDL is reported in mmol/L
- Abbreviations: N, number; T2DM, type-2 diabetes mellitus; DPN, diabetic peripheral neuropathy; SMD, standardized mean difference; Cl: Confidence interval
